Correlation of body mass index and serum parameters with ultrasono-graphic grade of fatty change in non-alcoholic fatty liver disease

Iranian Red Crescent Medical Journal

Volumn 16, Issue 1, 2014, Pages

  Abangah, Ghobad ^a   Yousef, Atefeh ^a   Asadollahi, Rouhangiz ^a   Veisani, Yousef ^a   Rahimifar, Paria ^a   Alizadeh, Sajjad ^a  

^a ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aspartate aminotransferase; Body mass index; Non alcoholic fatty liver disease; Triglyceride; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CERULOPLASMIN; FERRITIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; PLASMA PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; THYROTROPIN; TRANSFERRIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DIET RESTRICTION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN ELECTROPHORESIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84891688210     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: 10.5812/ircmj.12669     Document Type: Article

References (49)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339-350.
2. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007;6(6):572-578.
3. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115(5):141-150.
4. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Se-min Liver Dis. 2004;24(4):349-362.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231.
6. Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol. 2013;2013:450639.
7. Qian Y, Fan JG. Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int. 2005;4(2):173-177.
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, Mc-Cullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-1419.
9. Jamali R, Pourshams A, Amini S, Deyhim MR, Rezvan H, Male-kzadeh R. The upper normal limit of serum alanine amino-transferase in Golestan Province, northeast Iran. Arch Iran Med. 2008;11(6):602-607.
10. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepa-tol. 2012;27(10):1555-1560.
11. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-161.
12. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6(3):161-163.
13. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124(1):71-79.
14. Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet. 2005;18(5):365-370.
15. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18(5):588-594.
16. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-1725.
17. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-750.
18. Kennedy Gillian. Non-alcoholic fatty liver disease: Can ultrasound assist in early diagnosis of prediabetes and delay progression to type2 diabetes mellitus. Sound Effects. 2009.
19. American Gastroenterological Association. American Gastroen-terological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1702-1704.
20. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology. 1989;172(2):389-392.
21. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11(6):560-565.
22. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16.
23. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126(2):137-145.
24. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15(5):539-543.
25. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49(1):89-96.
26. Sogabe M, Okahisa T, Tsujigami K, Fukuno H, Hibino S, Yamanoi A. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome. Hepatol Res. 2013.
27. Lin YC, Chou SC, Huang PT, Chiou HY. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. Ann Hepatol. 2011;10(2):125-132.
28. Ye J, Chen Z, Wang T, Tong J, Li X, Jiang J, et al. Role of tissue disorder markers in the evaluation of disease progress and outcome prediction: a prospective cohort study in non-cardiac critically ill patients. J Clin Lab Anal. 2010;24(6):376-384.
29. Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M. The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr. 2012;124(15-16):526-531.
30. Kotronen A, Yki-Jarvinen H, Mannisto S, Saarikoski L, Korpi-Hyovalti E, Oksa H, et al. Non-alcoholic and alcoholic fatty liver disease - two diseases of afuence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health. 2010;10:237.
31. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012;11(5):513-520.
32. Obesity epidemic puts millions at risk from related diseases. WHO Press Release. 1997;46:12.
33. Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci. 1993;38(12):2145-2150.
34. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85(1):37-45.
35. National Cholesterol Education Program Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fnal report. Circulation. 2002;106(25):3143-3421.
36. American Diabetes Association. Standards of medical care in dia-betes--2010. Diabetes Care. 2010;33 Suppl 1:S11-S61.
37. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-3167.
38. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714-1719.
39. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820-826.
40. Miksztowicz V, Lucero D, Zago V, Cacciagiu L, Lopez G, Gonzalez Ballerga E, et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev. 2012;28(6):535-541.
41. Novakovic T, Inic Kostic B, Milinic S, Jovicevic L, Dzeletovic G. [Cardiovascular disease risk factors in patients with non-alcoholic fatty liver disease]. Med Pregl. 2013;66(1-2):24-31.
42. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-119.
43. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism. 2006;55(12):1604-1609.
44. Rafeey M, Mortazavi F, Mogaddasi N, Robabeh G, Ghafari S, Hasani A. Fatty liver in children. Ther Clin Risk Manag. 2009;5(2):371-374.
45. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006;18(3):233-237.
46. Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids. 2010;45(4):321-327.
47. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52(4):579-585.
48. Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chi-anese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72.
49. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754.